Key facts
- This page summarizes Gary S. Gillheeney's Form 4 filing for Organogenesis Holdings Inc. (ORGO).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Feb 2026, 17:27.
Gary S. Gillheeney - 18 Feb 2026 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ORGO
- Reported as of
- 18 Feb 2026
- Net transaction value
- -$347,128
- SEC form
- 4
- Accepted by SEC
- 20 Feb 2026, 17:27:50 UTC
- Prior SEC filing
- 18 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ William R. Kolb, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gary S. Gillheeney filed Form 4 for Organogenesis Holdings Inc. (ORGO) on 20 Feb 2026.
Change
- Previous filing in this sequence was filed on 18 Feb 2026.
- Current net transaction value: -$347,128.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001757373
Primary reporting owner
Gillheeney Gary S.
- Relationship
- President and CEO, Director
- Address
- C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON
- Signature
- /s/ William R. Kolb, Attorney-in-Fact
- Signature date
- 20 Feb 2026
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORGO
transaction
Class A Common Stock
Award
- Transaction value
- $0
- Shares
- +890,625
- Change %
- +27%
- Price
- $0.000000
- Shares after
- 4,134,542
- Date
- 18 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
ORGO
transaction
Class A Common Stock
Award
- Transaction value
- $0
- Shares
- +186,968
- Change %
- +4.5%
- Price
- $0.000000
- Shares after
- 4,321,510
- Date
- 18 Feb 2026
- Ownership
- Direct
- Footnotes
- F2
ORGO
transaction
Class A Common Stock
Tax liability
- Transaction value
- $347,128
- Shares
- -90,398
- Change %
- -2.1%
- Price
- $3.84
- Shares after
- 4,231,112
- Date
- 18 Feb 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORGO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +507,795
- Change %
- Price
- $0.000000
- Shares after
- 507,795
- Date
- 18 Feb 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 507,795
- Exercise price
- $3.84
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.
Footnote F2
Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.
Footnote F3
The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.